- Home
- ESLA vs RAND Comparison
ESLA vs RAND Comparison
Compare ESLA & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- RAND
- Stock Information
- Founded
- ESLA 2021
- RAND 1969
- Country
- ESLA United States
- RAND United States
- Employees
- ESLA N/A
- RAND N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- RAND Finance: Consumer Services
- Sector
- ESLA Health Care
- RAND Finance
- Exchange
- ESLA Nasdaq
- RAND Nasdaq
- Market Cap
- ESLA 48.9M
- RAND 44.7M
- IPO Year
- ESLA N/A
- RAND N/A
- Fundamental
- Price
- ESLA $1.30
- RAND $14.11
- Analyst Decision
- ESLA Strong Buy
- RAND
- Analyst Count
- ESLA 1
- RAND 0
- Target Price
- ESLA $16.00
- RAND N/A
- AVG Volume (30 Days)
- ESLA 116.2K
- RAND 4.0K
- Earning Date
- ESLA 11-20-2025
- RAND 11-05-2025
- Dividend Yield
- ESLA N/A
- RAND 11.88%
- EPS Growth
- ESLA N/A
- RAND N/A
- EPS
- ESLA N/A
- RAND N/A
- Revenue
- ESLA N/A
- RAND $7,966,118.00
- Revenue This Year
- ESLA N/A
- RAND N/A
- Revenue Next Year
- ESLA N/A
- RAND N/A
- P/E Ratio
- ESLA N/A
- RAND N/A
- Revenue Growth
- ESLA N/A
- RAND 1.16
- 52 Week Low
- ESLA $0.63
- RAND $13.82
- 52 Week High
- ESLA $1.78
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- ESLA 61.83
- RAND 40.18
- Support Level
- ESLA $1.22
- RAND $14.06
- Resistance Level
- ESLA $1.48
- RAND $15.07
- Average True Range (ATR)
- ESLA 0.14
- RAND 0.42
- MACD
- ESLA 0.01
- RAND -0.02
- Stochastic Oscillator
- ESLA 56.82
- RAND 8.33
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.